A company in Baltimore is personalizing cancer therapy by developing patient-derived tumor xenografts in mice to identify the most effective drugs for the patient.
The bump on the back of the mouse is the size of a Tic Tac breath mint, or, possibly, a small pea.
But for Matt Freedman, a New York artist grappling with a rare and deadly neck cancer, the tiny tumor — his tumor — represents a last-ditch hope for a healthy future.
Freedman, 57, who was diagnosed with adenoid cystic carcinoma in 2012, is among a small but growing group of cancer patients turning to a kind of very personalized medicine in which animals serve as stand-ins to treat human disease.
Called mouse avatars in some circles — like the virtual characters in online games — the critters are implanted with pieces of tumor harvested from their human counterparts. They’re then propagated to create a colony of animals in which to test drugs and other treatments that would be too aggressive — or take too long — to attempt in a person.
Read the complete report here: http://nbcnews.to/1hPhMeO
Source: NBC News
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
FDA Approves Tislelizumab for Advanced or Metastatic ESCC After Chemotherapy
March 15th 2024The FDA has approved tislelizumab-jsgr (Tevimbra) for single-agent use in adult patients with unresectable or metastatic esophageal squamous cell carcinoma following prior systemic chemotherapy that did not include a PD-1/PD-L1 inhibitor.
Read More